Literature DB >> 1292578

Hypertension in the elderly.

M E Safar1.   

Abstract

Publication of the SHEP study (Systolic Hypertension in the Elderly Programme) leaves no doubt that isolated systolic hypertension in the elderly should be treated. There are, however, a number of important outstanding questions: (a) the mechanism of reduction of morbidity, (b) because antihypertensive therapy appears to be more effective in elderly patients than in the young, when should treatment be started in relation to progression of age?, (c) besides the blood pressure elevation, what are the exact mechanical factors responsible for degeneration of the arterial wall?, and (d) what in 1993 is the definition of hypertension? These are questions that now need to be answered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1292578     DOI: 10.1007/bf00052559

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  5 in total

Review 1.  Salt and hypertension. Lessons from animal models that relate to human hypertension.

Authors:  L Tobian
Journal:  Hypertension       Date:  1991-01       Impact factor: 10.190

Review 2.  Therapeutic trials and large arteries in hypertension.

Authors:  M Safar
Journal:  Am Heart J       Date:  1988-03       Impact factor: 4.749

Review 3.  Ambulatory blood pressure monitoring: research and clinical applications.

Authors:  G Mancia
Journal:  J Hypertens Suppl       Date:  1990-12

4.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

5.  Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality.

Authors:  B Darne; X Girerd; M Safar; F Cambien; L Guize
Journal:  Hypertension       Date:  1989-04       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.